CASI · Casi Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $43.11M | $30.17M | $15.14M | $4.13M | $0 | $0 |
| Cost of Revenue | $15.83M | $12.56M | $9.51M | $0 | - | - |
| Gross Profit | $27.28M | $5.63M | $5.63M | $4.13M | - | - |
| R&D | $16.00M | $14.42M | $11.47M | $9.75M | $8.51M | $7.60M |
| SG&A | $23.45M | $23.77M | $19.66M | $27.34M | $18.00M | $3.16M |
| Total Operating Expenses | $61.31M | $59.45M | $66.67M | $51.09M | $27.19M | $10.75M |
| D&A | $1.20M | $468.0K | $562.0K | $603.0K | $365.6K | $117.8K |
| Operating Income | ($34.03M) | ($41.84M) | ($51.53M) | ($27.19M) | ($27.47M) | ($9.45M) |
| Interest Expense | $0 | $2.9K | $3.1K | $5.6K | $7.5K | - |
| Income Tax | $1.98M | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($41.01M) | ($36.65M) | ($48.29M) | ($46.03M) | ($27.47M) | ($10.77M) |
| EPS - Basic | - | ($0.44) | - | - | - | - |
| EPS - Diluted | - | ($0.44) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.11M | $38.70M | $57.06M | $53.62M | $84.20M | $43.49M |
| Accounts Receivable | $12.97M | $9.80M | $4.64M | $1.29M | - | - |
| Inventory | $6.14M | $1.91M | $1.36M | $4.54M | $283.0K | - |
| Accounts Payable | $3.29M | $4.79M | $3.67M | $5.11M | $968.0K | $2.09M |
| Current Assets | $73.42M | $61.97M | $74.03M | $61.50M | $92.56M | $43.81M |
| Total Assets | $96.23M | $138.30M | $127.73M | $102.63M | $113.41M | $45.10M |
| Current Liabilities | $17.00M | $13.19M | $7.98M | $7.95M | $3.87M | $5.06M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $29.30M | $30.34M | $24.16M | $8.97M | $3.95M | $6.56M |
| Stockholders' Equity | $44.57M | $84.50M | $81.54M | $73.00M | $109.46M | $38.54M |
| Retained Earnings | ($637.16M) | ($605.64M) | ($570.50M) | ($523.91M) | ($478.94M) | ($452.70M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.09M) | ($26.84M) | ($25.89M) | ($23.24M) | ($28.58M) | ($6.02M) |
| Investing Cash Flow | $31.16M | ($20.69M) | ($20.72M) | ($28.06M) | ($21.77M) | ($64.8K) |
| Financing Cash Flow | ($3.27M) | $29.64M | $47.15M | $22.05M | $92.27M | $28.05M |
| CapEx | $5.61M | $8.95M | $1.50M | $427.0K | $1.13M | $934.7K |
| Free Cash Flow | ($26.70M) | ($35.79M) | ($27.39M) | ($23.67M) | ($29.72M) | ($6.96M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 63.3% | 18.7% | 37.2% | 100.0% | - | - |
| Operating margin | -78.9% | -138.7% | -340.3% | -658.2% | - | - |
| EBITDA margin | -76.2% | -137.1% | -336.6% | -643.6% | - | - |
| Net margin | -95.1% | -121.5% | -318.9% | -1114.3% | - | - |
| Free cash flow margin | -61.9% | -118.6% | -180.9% | -573.0% | - | - |
| FCF / Net income | 0.65 | 0.98 | 0.57 | 0.51 | 1.08 | 0.65 |
| R&D / Revenue | 37.1% | 47.8% | 75.8% | 236.0% | - | - |
| SG&A / Revenue | 54.4% | 78.8% | 129.9% | 661.7% | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -42.6% | -26.5% | -37.8% | -44.9% | -24.2% | -23.9% |
| Return on equity | -92.0% | -43.4% | -59.2% | -63.1% | -25.1% | -27.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.32 | 4.70 | 9.28 | 7.74 | 23.89 | 8.65 |
| Quick ratio | 3.96 | 4.56 | 9.11 | 7.17 | 23.82 | 8.65 |
| Cash ratio | 2.77 | 2.94 | 7.15 | 6.75 | 21.74 | 8.59 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -14426.6x | -16621.3x | -4855.5x | -3662.9x | - |
| Equity multiplier | 2.16 | 1.64 | 1.57 | 1.41 | 1.04 | 1.17 |
| Liabilities / Assets | 0.30 | 0.22 | 0.19 | 0.09 | 0.03 | 0.15 |
| Efficiency | ||||||
| Asset turnover | 0.45 | 0.22 | 0.12 | 0.04 | 0.00 | 0.00 |
| Inventory turnover | 2.58 | 6.58 | 7.01 | 0.00 | - | - |
| Days sales outstanding | 110d | 119d | 112d | 114d | - | - |
| Days inventory outstanding | 142d | 55d | 52d | - | - | - |
| Days payable outstanding | 76d | 139d | 141d | - | - | - |
| Cash conversion cycle | 176d | 35d | 23d | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 42.9% | 99.2% | 266.5% | - | - | - |
| Revenue CAGR (3y) | 118.5% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | 216.5% | - | - | - |
| Gross profit growth (YoY) | 384.3% | 0.0% | 36.4% | - | - | - |
| Operating income growth (YoY) | 18.7% | 18.8% | -89.5% | 1.0% | -190.6% | - |
| Net income growth (YoY) | -11.9% | 24.1% | -4.9% | -67.6% | -155.1% | -13.9% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 25.4% | -30.7% | -15.7% | 20.3% | -327.1% | -11.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -47.3% | 3.6% | 11.7% | -33.3% | 184.0% | 85.4% |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-5.20
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CASI Pharmaceuticals against the 5 most active filers in the same SIC group.